Increase exposure of simvastatin. Bioavailability may be increased w/ grapefruit juice. May increase plasma conc w/ strong CYP3A4 inhibitors eg, ketoconazole, itraconazole, ritonavir. Increased risk of hypotension w/ clarithromycin. Plasma conc may decrease w/ CYP3A4 inducers eg, rifampicin, Hypericum perforatum
. May increase trough conc of cyclosporin. Risk of increased tacrolimus blood levels. May increase exposure of mTOR inhibitors eg, sirolimus, temsirolimus & everolimus.